Drug Approval | September 01, 2021
Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
